Functional Dyspepsia (Investigational Adjunct)
Investigational adjunct for functional dyspepsia (Rome IV criteria); H. pylori eradication when positive, proton pump inhibitors, prokinetics, and tricyclic antidepressants remain evidence-based.
Patienten-Zusammenfassung
- Ist dies FDA-zugelassen fuer diese Anwendung?
- Not FDA-cleared for functional dyspepsia. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for functional dyspepsia is investigational.
- Welche Evidenz existiert?
- Tier C (investigational). Only anecdotal reports; there are no randomized controlled trials. Evidence-based therapy for functional dyspepsia per ACG guidelines: test-and-treat for Helicobacter pylori (urea breath test or stool antigen, eradicate if positive), proton pump inhibitor trial, low-dose tricyclic antidepressant (amitriptyline 10-25 mg) for postprandial distress, prokinetics (metoclopramide short-course, itopride), and psychological therapies (cognitive-behavioral therapy, gut-directed hypnotherapy) for refractory cases. Alarm features require upper endoscopy.
- Hauptrisiken
- Bleeding from bite sites for 6 to 24 hours after detachment
- Bruising and tenderness over the upper abdomen
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Trigger of nausea or worsening dyspeptic symptoms
- Risk of missed underlying gastric ulcer, malignancy, or H. pylori infection
- Delay of proton pump inhibitor or H. pylori eradication therapy
- Substitution for low-dose tricyclic antidepressant or psychological therapy in refractory cases
- Wer dies nicht in Betracht ziehen sollte
- Patients with alarm features (unintentional weight loss, anemia, dysphagia, persistent vomiting, hematemesis, melena, palpable mass)
- Patients who have not been tested for Helicobacter pylori
- Patients with active peptic ulcer disease or gastric malignancy
- Patients on anticoagulants, with hemophilia, or with severe anemia
- Pregnant patients
- Patients who have not tried proton pump inhibitor for 4-8 weeks
- Was Sie Ihren Kliniker fragen sollten
- Have I been tested for Helicobacter pylori (urea breath test or stool antigen)?
- Have I had upper endoscopy if I have any alarm features?
- Have I tried a proton pump inhibitor for 4-8 weeks?
- Am I a candidate for low-dose tricyclic antidepressant (amitriptyline 10-25 mg)?
- Have I been offered cognitive-behavioral therapy or gut-directed hypnotherapy?
- What evidence specifically supports leech therapy for functional dyspepsia?
- What is the cost and is it covered by insurance? (typically not covered)
- Wann dringende medizinische Versorgung suchen
- Vomiting blood or coffee-ground material (possible upper GI bleeding)
- Passing black tarry stools (possible GI bleeding)
- Unintentional weight loss, anemia, or dysphagia (alarm features — endoscopy needed)
- Severe abdominal pain (possible peptic ulcer perforation)
- Persistent vomiting or inability to keep down food
- Spreading redness, warmth, pus, or red streaks (cellulitis)
- Fever above 38.0 C / 100.4 F or chills
- Hives, facial or tongue swelling, throat tightness, or breathing difficulty
Was dies NICHT bedeutet
- This is NOT FDA-cleared for functional dyspepsia.
- Anecdotal reports do NOT establish efficacy versus H. pylori eradication, proton pump inhibitor, or low-dose tricyclic antidepressant.
- It does NOT replace upper endoscopy when alarm features are present.
- It does NOT substitute for evidence-based pharmacologic and psychological therapy.
- It does NOT distinguish functional dyspepsia from peptic ulcer disease or gastric malignancy.
Sicherheits-Querverweise
Clinical Profile
- Category
- gastrointestinal
- ICD-10
- K30
- Safety tier
- medium
Evidence Summary
Functional dyspepsia (Rome IV) is epigastric pain or postprandial distress syndrome without identifiable structural or biochemical cause, after upper endoscopy and H. pylori testing. Evidence-based stepwise management is H. pylori eradication when positive, proton pump inhibitor trial (4-8 weeks), prokinetics (acotiamide where available, or metoclopramide short-term with cardiac caution), low-dose tricyclic antidepressants for refractory pain-predominant disease, and dietary modification. Hypnotherapy and cognitive behavioral therapy have RCT support. No published controlled trials of hirudotherapy exist for functional dyspepsia. Epigastric or upper-abdominal placement has been mentioned in Russian traditional-medicine literature without efficacy data and without consideration of bleeding risk in patients on aspirin or anticoagulants.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Untreated H. pylori infection (treat first)
- Active peptic ulcer disease or upper GI bleeding
- Aspirin, NSAID, or anticoagulant use
- Suspected gastric malignancy on endoscopy
- Prior gastric surgery or bariatric procedure
Related Conditions
Hemorrhoids (Grade II-III, Symptomatic)
Investigational use for symptomatic relief of grade II-III internal/external hemorrhoidal disease; does not address anatomic prolapse.
External Thrombosed Hemorrhoid (Acute, <72h)
Investigational adjunct for acute external thrombosed hemorrhoids presenting within 72 hours; distinct from internal hemorrhoidal disease.
Chronic Anal Fissure (>8 Weeks)
Investigational adjunct for chronic anal fissure refractory to medical therapy; very limited case-report evidence; surgical sphincterotomy remains gold standard.
Non-Alcoholic Fatty Liver Disease (Investigational Adjunct)
Investigational adjunct in NAFLD/MASLD; small case series only; weight loss, dietary modification, and resmetirom remain primary.